StockMarketWire.com - PureTech Health said its Vedanta Biosciences unit had commenced a clinical study of a treatment for the Clostridium difficile bowel infection.

The phase-two study of the treatment, VE303, was inspected to enroll up to 146 patients.

It would evaluate the safety and efficacy of two doses of VE303 compared to placebo in patients with the condition.




Story provided by StockMarketWire.com